OXIS International releases agenda for ergothioneine conference

OXIS International releases agenda for ergothioneine conference

OXIS Interntional, Inc. announces an impressive agenda slated for the upcoming First International Congress on Ergothioneine, featuring many of the world’s leading authorities on antioxidants and age management medicine.


OXIS Interntional, Inc. announces an impressive agenda slated for the upcoming First International Congress on Ergothioneine (www.ergocongress.com), featuring many of the world’s leading authorities on antioxidants and age management medicine. The conference will take place July 15-17, 2011, at the DeNeve Auditorium on the campus of UCLA in Westwood, California. This is the first ever meeting of its kind, gathering world experts in the fields of oxidative stress, healthy aging and chronic disease prevention and management. Feature presentations include those by members of Oxis’ “Blue Ribbon” Science Advisory Board and will focus on the unique properties and potential benefits of Ergothioneine, a powerful and newly rediscovered “super antioxidant.”

Leading members of the scientific community have stated that l-ergothioneine may be the most powerful and effective antioxidant ever discovered, with unparalleled potential benefits for cognitive function, eye health, immune modulation, lung health, reproductive health, skin health and overall wellness at all stages of the aging process. The large body of peer reviewed published research during the 100 years since the discovery of Ergothioneine has demonstrated these beneficial effects where inflammation and oxidative stress are key health challenges.

The conference begins on Friday, July 15, with opening remarks from Oxis’ distinguished advisory board:

· Okezie I. Aruoma, M.B.A., Ph.D., D.Sc., Touro College of Pharmacy, New York

· John Repine, M.D., Web-Waring Institute, University of Colorado

· L. Stephen Coles, M.D. Ph.D., UCLA Department of Chemistry and Biochemistry

The keynote lecture on Friday will feature Dr. Alexander Schauss, Ph.D., FACN, the CEO of AIBMR Life Sciences, who will discuss the importance of establishing safety for nutraceutical compounds and will present extensive data on the safety of Ergothioneine.

Throughout the conference, distinguished speakers will provide unique perspectives, data and insights on these critical areas of emerging science.

The faculty includes:

· Bruce N. Ames, Ph.D., Children’s Hospital, Oakland Research Institute

· Stephen G. Clarke, Ph.D. Director, Molecular Biology Institute, UCLA

· Dirk Grundemann, Ph.D., University of Cologne, Germany

· Young Joon Surh, Ph.D., College of Pharmacy, Seoul National University, Korea

· Marvin Housman, M.D., Total Nutraceutical Solutions, Stevenson, Washington

Presentations will focus on evidence-based research discussing the unique properties and potential benefits of Ergothioneine, comparing and contrasting with other approaches. A complete speaker agenda is available at www.ergocongress.com/agenda.

The conference is geared to healthcare professionals, wellness advocates, pharmaceutical scientists, physicians and pharmacists, alternative and complementary health practitioners and all those health professionals with an interest in the latest information on antioxidants and their role in the maintenance of good health throughout the aging process. Attendees will earn AAFP continuing education credits.

About OXIS International, Inc.

OXIS International, Inc. is a long-established, but recently revitalized biotechnology Company developing multiple proprietary, natural substance-based products focused on oxidative stress and inflammation, which are associated with the negative effects of free radicals and reactive oxygen species (ROS). The Company’s consumer product portfolio is quickly expanding to include dietary supplements, functional foods and beverages, skin care and other personal care products, and animal health products. Specifically, Oxis is emphasizing the unique properties of L-Ergothioneine (ERGO), a highly potent, patent-protected and versatile antioxidant. The Company recently signed a strategic financing agreement with its primary product development and manufacturing partner, Gemini Pharmaceuticals, launched its first product, ErgoFlex, for joint pain relief and overall joint health and announced a joint venture with engage:BDR for a global leader in online sales and marketing. For more information, please visit www.oxis.com.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish